Alisporivir (Debio-025) is a cyclophilin inhibitor molecule.It has potent anti-hepatitis C virus (HCV) activity.

Alisporivir (Debio-025) is an analogue of cyclosporine A and represents the prototype of a new class of non-immunosuppressive cyclophilin inhibitors. DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication[1]. Alisporivir prevents HCV protein-mediated collapse of the respiration-driven mitochondrial membrane potential. Alisporivir prevents HCV protein-mediated mitochondrial dysfunction outside the context of apoptosis, calcium overload, production of ROS, dysfunction[2]. Alisporivir pretreatment stimulates antigen presentation by hepatoma target cells, leading to enhancement of antigen-specific CD8+ T cell activation by 40%. Alisporivir induces an increase of MHC-I and beta-2 microglobulin on the surface of several cell lines[4]. In cell culture models, low-micromolar doses of alisporivir block SARS-CoV and MERS-CoV replication. Combination treatment with alisporivir and ribavirin increases the anti-MERS-CoV activity in cell culture[3].

Combination treatment with alisporivir and ribavirin does not protect against SARS-CoV infection in a mouse model[3].

254435-95-5

C63H113N11O12

1216.64

Debio-025;DEB-025;Alisporivir

DMSO:100 mg/mL (82.19 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years